Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
C11 agree with your point room for more than one type of cancer vaccine Heather Shaw referred to “ these will be game changers in immunology “
See Bermuda post on ASCO earlier in the week . Also heather shaw in on the advisory board for the Scope Trial
Skin cancer jab trial targets high-risk melanomas
https://www.thetimes.co.uk/article/e23343c5-91c4-49b0-9fa4-c1eec5c2bb2c?shareToken=6d03ef8920e19e9d3d4fd5f793fc9d06
Dr Heather Shaw, consultant medical oncologist and the national co-ordinating investigator for the trial, said: “I think there is a real hope that these will be the gamechangers in immunotherapy.”
Each patient has their own personalised jab manufactured within weeks, using mRNA genetic code found in their tumours. When injected, the jab instructs the body to create proteins identical to those found on the surface of tumours, triggering an immune response.
From Bermuda shorts
Really good to see that Heather Shaw, one of the SCIB1 study investigators will be presenting a poster at ASCO in Chicago in June.
SCIB1 & iSCIB1+ - Scancell
The abstract title:-
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.
Presenter: Heather May Shaw, MD, FRCP, MRCP | Mount Vernon Cancer Center
Abstract: 9535
| Poster Bd #: 319
ASCO isn't just another scientific conference, it's the largest oncology conference in the world and it would have been disappointing if Scancell were not represented.
Chelsea
Absolutely spot on.
IMO, it won’t be a case of either MRNA, or DNA as an available treatment option and there will be room for both as ammo against melanoma. In the same way that there are often multiple treatment options for other diseases. Assuming of course that trial data proves they both work well.
The publicity is positive on a number of fronts. Scancell now need to get their own data published. We already know that should be this year and we’re already in April, so it’s just a handful of months away.
Explains why recruitment has been a little slow....Moderna will be first in the queue!
I like the way the BBC website article has the quote 'you couldn't give this to the next patient in the line because you wouldn't expect it to work.
"It's truly personalised."'
Makes it.sound like an advantage rather than a drawback. If Scancell vaccines come along as hoped, imagine the quotes available for them - ' off the shelf', 'universal' etc.
Just have to wait and see.
I see the story is headline news in some newspapers and contained in that story is Dr Heather Shaw, national co-ordinating investigator for the trial.
Https://www.bbc.co.uk/news/health-68897731
Can't say I was aware of this trial before, and I note it is a Phase 3 trial so earlier phases were apparently more under the radar (for me anyway).
I see some positives from this story:
- the combination with Pembro and Keytruda is validated
- results from this trial (49% improvement) will provide a comparison to SCIB1
- this is a personalised (expensive) treatment.
Hopefully we'll get this kind of front page coverage one day.
A clip from nanaco “moditope has passed phase 1 and is showing positive signs”
Is this for real ? No wonder big Pharma don’t show any sign of interest
Violin, Sadly only telling It as I see It. Who and Why the consistent selling?. Unfortunately topped up at the last dilution. Fortunately Not a lot. Last placing @ 11P today's SP 9.50P IMO.
Good find Cleaner. I see that this relates to the partnership with Vaccitech announced 7 November’22. I wonder if we will have a Phase 1 study this year:-
https://www.lse.co.uk/rns/SCLP/licenses-vaccitech-technology-to-advance-modi-2-5arpm4twcqxzkuu.html
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "We are pleased to partner with Vaccitech to take the second candidate from our Moditope® platform through GMP and subsequent clinical development. With its elegant and effective solution, the SNAPvax™ technology provides an excellent method for formulation of the Modi-2 vaccine. Combining this technology with our expertise will allow us to develop a rapid manufacturing process for Modi-2, with the hope that we can bring it into a Phase 1 clinical study during 2024."
If no value why pay $200m ? It seems scan is good in posters and repeating ample times the same message.
Burn cash and next round of dilution will be lower than the 11p. If concrete then give up some info if not stop promoting a dream by claiming encouraging promising exciting and the rest of wishful thinking outcome. And please take if hope and other BS descriptive words from future communication
wednesday 7 th of august 11:25 am
modi-2, a vaccine targeting ****citrullinated self-epitopes, stimulates potent cd4-mediated anti-tumor responses as a therapy for solid cancers
https://www.immuno-oncologysummit.com/cancer-vaccines?utm_source=linkedin&utm_medium=social&utm_campaign=vjm_final_track_agenda_20240423
abdullah al-omari, phd, scientist, t cell vaccine, scancell ltd.
stresses within the tumor microenvironment mediate post-translational modifications of self-proteins. ****citrullination is the conversion of lysine residues to ****citrulline which can generate neoepitopes and bypass self-tolerance. modi2, a ****citrullinated peptide-snapvax vaccine, stimulates strong th1 responses and anti-tumor immunity in three different murine tumor models. we propose the modi-2 vaccine formulation has potential for translation into clinic in several cancer indications.
Drac, you are correct re the sales..as for Redmile...whatever raises the SP...nothing else is achieving this, even after the numerous conferences.
A whiff of desperation (i.e. ill thought out comments ) in quite a few posts of late IMO.
Interesting.
I think even you known the answer to that Dracula.
You'll have to try a lot harder to bridge your credibility gap.
With No interest. Will the big Investors take Sclp private for say a low ball offer of say £200 Ml ?.
Nothing new at all, from “AI Powered Pharmaceutical Intelligence”
Https://synapse.patsnap.com/drug/ceab59ba703544a2a1d8c8da9b59e11a
Doesn't surprise me, but these are generic titles so may present a more broad overview of cancer vaccines in the melanoma space. Especially as they cover different patient demographic groups.
Thanks for that Burble. I think she's also an investigator for the Moderna mRNA vax.
It seems she also presented at the Association of Cancer Physicians event on the 1st March 2024 in the New Therapies session delivering a presentation titled 'cancer vaccines: trials and the future - where are we now?' Interesting tweet about it https://x.com/drlennardlee/status/1763629978430669099 'There was spontaneous applause when we heard what she was achieving in the #cancervaccine space!'
Ruck
Just to remind you
Sheffield United 1 Burnley 4
Bring on Man United next 😀
Bermuda,
Dr Shaw is also presenting at the Oncology Forum (https://oncology-forum.co.uk/wp-content/uploads/2024/04/2024-UK-Oncology-Forum_DRAFT-Programme-4.pdf) in a breakout session titled 'multidisciplinary challenges for modern melanoma clinical practice' with a half hour talk entitled 'vaccines in early and advanced melanoma'.
This meeting is only open to UK cancer healthcare professionals, and has breakout sessions for the main cancer types.
TF,
I must have blocked that from my memory as half the family are big SUFC fans. UTB
Yes Ruck and good for them ! What a fine result Burnley had, walloping Sheffield United the other day. Come on Burnley !